The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation
Open accessAbstract
Natural killer (NK) cells contribute to the first line of defense against viruses and to the control of tumor growth and metastasis spread. The discovery of HLA class I specific inhibitory receptors, primarily of killer Ig-like receptors (KIRs), and of activating receptors has been fundamental to unravel NK cell function and the molecular mechanisms of tumor cell killing. Stemmed from the seminal discoveries in early ‘90s, in which Alessandro Moretta was the major actor, an extraordinary amount of research on KIR specificity, genetics, polymorphism and repertoire has followed. These basic notions on NK cells and their receptors have been successfully translated to clinical applications, primarily to the haploidentical haematopoietic stem cell transplantation to cure otherwise fatal leukemia in patients with no HLA compatible donors. The finding that NK cells may express the PD-1 inhibitory checkpoint, particularly in cancer patients, may allow to understand how anti-PD-1 therapy could function also in case of HLA class Ineg tumors, usually susceptible to NK-mediated killing. This, together with the synergy of therapeutic anti-checkpoint monoclonal antibodies, including those directed against NKG2A or KIRs, emerging in recent or ongoing studies, opened new solid perspectives in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380 · cited 1×
“(197) reported a 5-year survival probability of ∼60% in adult AML patients in case of donor NK alloreactivity (KIR/KIR-L mismatch in graft vs.”
BackgroundIshida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687 · cited 2×
“In late ‘80s, the “missing self-hypothesis,” proposed by Karre and Ljunggren, inspired the subsequent seminal discoveries in mice and humans in early ‘90s (5).”
BackgroundHLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
Braud, V. M., Allan, D. S. J., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., et al. (1998) · Nature · doi:10.1038/35869 · Cited by 2,227
Innate Lymphoid Cells: 10 Years On
Vivier, E., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl, G., Koyasu, S., Locksley, R. M., McKenzie, A. N. J., Mebius, R. E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.017 · Cited by 2,124
Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778
Self-citationThe IPD and IMGT/HLA database: allele variant databases
Robinson, J., Halliwell, J. A., Hayhurst, J. D., Flicek, P., Parham, P., & Marsh, S. G. E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1161 · Cited by 1,740
The biology of innate lymphoid cells
Artis, D., & Spits, H. (2015) · Nature · doi:10.1038/nature14189 · Cited by 1,634
Licensing of natural killer cells by host major histocompatibility complex class I molecules
Kim, S., Poursine-Laurent, J., Truscott, S. M., Lybarger, L., Song, Y.-J., Yang, L., French, A. R., Sunwoo, J. B., Lemieux, S., Hansen, T. H., et al. (2005) · Nature · doi:10.1038/nature03847 · Cited by 1,340
André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,221
Cited by
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Pan, K., Farrukh, H., Chittepu, V. C. S. R., Xu, H., Pan, C.-X., & Zhu, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02327-z · Cited by 657
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 618
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
Tumor-Infiltrating Natural Killer Cells
Cózar, B., Greppi, M., Carpentier, S., Narni-Mancinelli, E., Chiossone, L., & Vivier, E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0655 · Cited by 476
NK cells and ILCs in tumor immunotherapy
Sivori, S., Pende, D., Quatrini, L., Pietra, G., Della Chiesa, M., Vacca, P., Tumino, N., Moretta, F., Mingari, M. C., Locatelli, F., et al. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100870 · Cited by 270
Self-citationGenova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., Gangemi, R., Filaci, G., Coco, S., & Croce, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799455 · Cited by 260
Wang, L. L., Janes, M. E., Kumbhojkar, N., Kapate, N., Clegg, J. R., Prakash, S., Heavey, M. K., Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10214 · Cited by 162
Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors
Quamine, A. E., Olsen, M. R., Cho, M. M., & Capitini, C. M. (2021) · Cancers · doi:10.3390/cancers13112796 · Cited by 39
HLA’s hidden hand in Alzheimer’s disease—five research questions en route to an answer
Capitani, L., & Carpanini, S. M. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf438 · Cited by 4
Cis-regulatory evolution of the recently expanded Ly49 gene family
Fan, C., Xing, X., Murphy, S. J. H., Poursine-Laurent, J., Schmidt, H., Parikh, B. A., Yoon, J., Choudhary, M. N. K., Saligrama, N., Piersma, S. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48990-y · Cited by 3
Metadata
- Authors
- Pende, D., Falco, M., Vitale, M., Cantoni, C., Vitale, C., Munari, E., Bertaina, A., Moretta, F., Del Zotto, G., Pietra, G., Mingari, M. C., Locatelli, F., & Moretta, L.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-05-28
- Volume
- 10
- Pages
- 1179-1179
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2946946191
- Cited by
- 389
- References
- 173
- FWCI
- 14.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.